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Summary
Background: Zollinger-Ellison syndrome is a very rare disease caused by tumor with gastrin producing cells
accompanied by hypergastrinemia leading to gastric hypersecretion and peptic ulcers and
their complications.
Case study: Female case of gastrinoma (Zollinger-Ellison syndrome; Z-E) with a record of 38 yrs of sur-
vival. Acute gastro-duodenal ulcers started at 28 yr of age and Z-E was diagnosed by using
gastrin assays. Basal and maximal acid outputs and ratio of basal/maximal outputs were away
over normal limits. Because of ulcer recurrence and complications, patient was subjected to
several gastric surgeries but refused total gastrectomy. She was also treated with many 
H2-receptor (R) antagonists and proton-pump inhibitors (PPI), each new drug being initially
highly effective but then showing declinig efficacy except when PPI, lansoprazole was used.
The gastrin level rose in the course of disease from initial high value of 2000 pg/mL to the
extreme 4500 ng/mL at present. During the last 2 yrs, metastasis mainly to liver developed
and they were successfully treated by synthetic octapeptide derivative of somatostatin and, as a
result, metastatis partly reduced and plasma gastrin drasticly decreased. Biopsy taken from
liver metastasis showed the presence of typical gastrinoma cells with gastrin and chromo-
granin, while that from oxyntic mucosa revealed the ECL-cell hyperplasia with carcinoid
tumors and unexpected gastric atrophy.
Conclusions: This phenomenal case described in this article might be the new proven evidence needed by
gastroenterologists to overturn the traditional treatment using total gastrectomy as a treat-
ment of choice to the partial gastrectomy combined with proton pump inhibitors.
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BACKGROUND
General consideration: Pancreatic Endocrine
Tumors (PET) vs Gastrinoma
Gastrinoma originally described by Zollinger and Elli-
son [1] and known as a cause of Zollinger-Ellison (Z-E)
syndrome shows an estimated incidence in USA ranging
from 0.1 to 1% of peptic ulcer patients [2]. It is one of
seven PET including; insulinoma, glucagonoma, VIPo-
ma (vasoactive intestinal peptide-secreting) causing the
Verner-Morrison syndrome or WDHA syndrome
(watery diarrhea, hypokalemia, and achlorhydria),
somatostatinoma, GRFoma (growth hormone releasing
factor–secreting), and nonfunctional tumors [3]. In all
cases except the non-functional tumors, ectopic hor-
mone release is associated with a distinct clinical syn-
drome. With non-functional tumors, the clinical symp-
toms and signs are entirely caused by the presence of
the tumor and almost all PET cells express chromo-
granin. Furthermore, all PET cells share certain com-
mon features, including various aspects of their natural
history, pathologic changes, medical treatment options,
approaches to tumor localization, surgical options, and
treatment options when the tumor has metastasis [4].
The PET are generally slow growing and effective ther-
apy requires both management of the effects of ectopic
hormone overproduction and therapy directed at the
tumor itself. In each of these tumors, surgical resection
of primary tumor, total pancreatic resection, Whipple’s
resection (with or without gastrectomy) is the treatment
of choice. However, at the time of diagnosis, most of the
PET already develop metastasis, therefore, the only rea-
sonable approach is to control clinical syndrome caused
by ectopic hormone release. In case of gastrinoma, total
removal of the stomach was originally thought to be the
only rational approach because the life-threatening
complications are due to acute gastro-duodeno-jejunal
ulcerations. With increased ability to control the symp-
toms of excessive hormone production, the prognosis
increasingly depends upon the therapy applied that in
case of gastrinoma appear to be potent gastric H+
inhibitors such as H2-R antagonist and proton pump in-
hibitor (PPI).
The proper diagnosis of PET requires constant aware-
ness of the presenting manifestations of the syndromes
and in each instance, except non-functional tumors, the
early symptoms are caused by the actions of the ectopi-
cally released hormone. Late in the course of disease,
symptoms are caused mainly by metastasis spread of the
tumor per se (pain, bleeding, cachexia).
The types of PET
PET may occur alone as sporadic tumor [5] or as a part
of an inherited disorder. PET may occur as multiple
endocrine neoplasia type 1 (MEN-1) (non-functional
status > gastrinoma > insulinoma > GRFoma > VIPo-
ma > glucagonoma), von Recklinghausen disease (duo-
denal somatostatinoma), von Hippel-Lindau disease
(nonfunctional), and tuberous sclerosis [6].
Gastrinoma, similarly to other PET, is an indolent yet
malignant neuroendocrine tumor characterized by gas-
tric acid hypersecretion and severe peptic diathesis,
intestinal hypermotility and steatorrhoe secondary to
excessive release of gastrin from non-beta-cell endocrine
neoplasm.
Distribution of gastrinoma
Although initial studies observed that the majority (up
to 80%) of gastrinomas occur within the pancreas, 10
modern diagnostic studies coupled with aggressive sur-
gical intervention have revealed that a large number of
gastrinomas are extrapancreatic and extraintestinal
[7,8]. Greater than 80% of gastrinomas have been local-
ized in the anatomical area known as the gastrinoma tri-
angle [9]. The boundaries of this triangle include the
confluence of the cystic and common bile ducts superi-
orly, the junction of the second and third portions of
the duodenum inferiorly, and the junction of the neck
and body of the pancreas medially. The most common
extrapancreatic site is the duodenum, wherein up to
40% to 50% of gastrinomas arise [10,11]. Other less
common extrapancreatic sites include the stomach,
bones, ovaries, liver, heart, and lymph nodes, which
together account for less than 10% of gastrinomas.
Greater than 50% of gastrinomas are considered to be
malignant. Solitary pancreatic lesions were found in less
than 30% of the earliest reported gastrinoma patients
[12]. With the more recent trend toward earlier mea-
surement of serum gastrin and exploratory surgery
[13], the incidence of metastatic disease at the time of
operation has decreased. Nevertheless, multiple tumors
or metastatic lesions are still observed in 30% to 55% of
patients at the time of diagnosis [10] (Fig. 1).
Morphology of gastrinoma
The neoplastic cells in gastrinomas show heterogeneity
[14–15]. The gastrin-producing cells are generally well
differentiated and contain histologic markers characteris-
Figure 1. Localization of gastrinoma in the pancreas and duodenum.
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tic of endocrine neoplasms in general, that is, they con-
tain chromogranin, neuron-specific enolase, and tyrosine
hydroxylase. Gastrinomas contain various types of secre-
tory granules that can vary in ultrastructural appearance
from those typically found in antral G cells. The degree
of malignancy does not appear to correlate with histolog-
ic appearance of gastrinoma, however, this observation
must be tempered by the knowledge that tumor aggres-
siveness is usually determined retrospectively.
Pathophysiology of gastrinoma: PET and hormone
release
As in the case of other endocrine neoplasms, gastrinomas
have been found to express a variety of neuroendocrine
peptides besides gastrin, including somatostatin, pancre-
atic polypeptide, adrenocorticotrophic hormone, and
vasoactive intestinal polypeptide (VIP). Although the
clinical manifestations are generally associated with over-
production of one hormone, case reports illustrating
combined syndromes have been described [16–19].
As mentioned before, gastric acid hypersecretion and
severe peptic ulcer diathesis secondary to excessive and
uncontrolled release of gastrin from tumor endocrine
cells lead to Z-E syndrome (Fig. 2). The neoplastic pan-
creatic cells secreting gastrin are thought to arise from
the ductular epithelium and not from cells of the islets
of Langerhans, despite the appellation of gastrinomas as
‘islet cell tumors’ [1]. Normally, the adult pancreas does
not secrete gastrin, but the fetal pancreas contains large
quantities of this peptide [20]. After birth, the gastrin-
secreting cells in the pancreas disappear and are not
seen again except as benign or malignant neoplasms in
Zollinger-Ellison syndrome. Gastrin is found predomi-
nantly in the gastric antrum and located in endocrine
G-cells [20] and functions as the primary stimulant of
postprandial gastric acid secretion. [21,22] (Fig. 3). The
stimulatory action may occur directly on the parietal cell
[23] through specific membrane receptors (CCKA)
[23,24] or indirectly via stimulation of CCKA-receptors
of the enterochromaffin-like (ECL) cells that release his-
tamine to activate H2-R of parietal cells and HCl secre-
tion [25]. Gastrin also has a well established trophic
effect on gastrointestinal tissues including oxynthic
mucosa and colon mucosa [26,27] (Fig. 4). In small
doses the peptide has been shown to increase protein
and DNA synthesis and total DNA content of gastric and
colon mucosa. In Z-E syndrome, the hypergastrinemia
that results from the release of peptide from an
endocrine neoplasm free of the usual regulatory
restraints has two synergistic effects on the stomach:
overstimulation of gastric parietal cells to secrete HCl
and increased mass of parietal and ECL cells and one
on the colon promoting mucosal cell proliferation and
growth. The potentiated gastric acid hypersecretion that
results is presumably the cause of the clinical manifesta-
tions (i.e, acid peptic disease and diarrhea) of the gastri-
noma or Z-E syndrome.
Expression of gastrin and its precursors in gastrinoma
Although it is well established that gastrinomas contain
and secrete large concentrations of the biologically
active fully processed molecular forms of gastrin, recent
Figure 2. Pathogenesis of Z-E syndrome.
Figure 3. Gastrin is released normally from antral G-cells to stimulate
acid secretion and growth of fundic mucosa and colon mu-
cosa and to protect this mucosa against noxious substances.
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studies indicate that altered posttranslational processing
of progastrin may be a feature of the disorder as well
[27]. Gastrin is synthesized as a large precursor mole-
cule, preprogastrin, that subsequently undergoes a
series of posttranslational processing steps involving
proteolytic cleavage as well as carboxyl-terminal amida-
tion (Fig. 5). The end products are a variety of molecu-
lar forms of amidated gastrin, including those 17 (G17)
and 34 (G34) amino acids in length [27] which are
found in G-cells of normal antral tissues and also in
tumor cells of gastrinoma and in sera of Z-E patients
[27]. Kariya and colleagues [28] examined the expres-
sion of the human gastrin gene by Southern blot analy-
sis and observed that DNA from gastric antrum and gas-
trinoma were indistinguishable from each other without
evidence of genomic rearrangements in the tumor tis-
sues. By immunochemical analysis, however, Dockray
and Walsh [29] were first to observe an unusual compo-
nent of gastrin in the sera of some Z-E syndrome
patients. Using region-specific antisera directed toward
the amino terminus of G17, they detected high circulat-
ing concentrations of what appeared to be the amino-
terminal tridecapeptide fragment of G17 (G171–13),
suggesting the presence of altered gastrin processing in
gastrinoma tissues. On the basis of information obtained
from the gastrin cDNA sequence [27–33] several investi-
gators have developed region-specific antisera toward
progastrin and its processing intermediates and utilized
them to examine the posttranslational processing of the
peptide in gastrinoma patients. These studies have con-
Figure 4. Gastrin stimulates ECL cells to release histamine, which in turn activates H2-R and H
+-K+ pump of parietal cells to secrete acid.
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firmed that gastrin processing is altered in tumor tissue.
The biological significance of these observations is
unclear, but one hypothesis is that the degree of altered
processing may correlate with the state of de-differentia-
tion of a tumor [27]. This correlation was examined by
Kothary and associates [33,34] who suggested that a
high ratio of amino-terminal G17 to carboxyl-terminally
amidated G17 immunoreactivity, indicative of incom-
plete posttranslational processing may signal the pres-
ence of tumor metastasis [27]. It is of interest that such
disturbed posttranslational processing, of gastrin was
detected recently in colon cancer, whose cancer cells are
also capable of expressing gastrin and its precursor pro-
gastrin that fails to affect gastric HCl secretion but
exerts marked trophic effects on other cancer cells. The
question remains whether gastrin and progastrin pro-
duced by gastrinoma cells are also capable of self-stimu-
lation by these peptides as it is the case of gastric and
colorectal cancer.
Differential diagnosis of Z-E syndrome
The hallmark of Z-E syndrome is the presence of circu-
lating hypergastrinemia [36]. Fasting serum gastrin lev-
els in normal subjects and in patients with routine pep-
tic ulcer disease are usually less than 150 pg/mL [37].
The degree of hypergastrinemia in patients with Z-E
syndrome varies greatly. Although occasional reports of
normal levels [37–39], virtually all gastrinoma patients
have fasting levels greater than 150 pg/mL, with levels
exceeding 100,000 pg/mL in some. A serum gastrin
level of greater than 1000 pg/mL in the right clinical
setting is virtually diagnostic of Z-E syndrome; however,
many patients do not have this level of hypergastrine-
mia. Elevated serum gastrin levels are seen in a number
of other clinical conditions as well. With the ever-
increasing use of potent antisecretory agents such as
long-acting H2-R antagonists and PPI (omeprazole, lan-
soprazole, pantoprazole), drug-induced hypergastrine-
mia [40] must be excluded prior to proceeding with an
extensive diagnostic evaluation for Z-E syndrome. The
mechanism by which these drugs induce hypergastrine-
mia is inhibition of gastric acid secretion. The level of
hypergastrinemia is reversible with drug cessation and
is usually less than 1.5 to 2 times normal levels. The dis-
covery that H. pylori infection leads to peptic ulcer dis-
ease is also an important consideration in the differen-
tial diagnosis of Z-E (Fig. 6). A significant percentage of
patients with H. pylori infection and peptic disease devel-
op hypergastrinemia and gastric acid hypersecretion
which are reversible with eradication of the organism
[41,42]. The H. pylori infection may mimic the clinical
and biochemical picture of Z-E syndrome, therefore,
careful search and eradication of H. pylori is mandatory
in any patient with peptic ulcer disease prior to consid-
ering a diagnosis of gastrinoma.
Hypergastrinemia unrelated to gastrinoma
The most common cause of hypergastrinemia is gastric
atrophy [43]. Gastric acid is the primary inhibitor of
gastrin release from antral G-cells; therefore, in its
absence an uninhibited secretion of the hormone occurs
with concomitant hyperplasia of G cells. Such hypergas-
trinemia is typically observed in pernicious anemia [43].
Up to 75% of patients with pernicious anemia have sub-
stantial hypergastrinemia. The gastrin levels in these
patients can approximate those found in gastrinoma
patients, reaching values greater than 1000 pg/mL.
Chronic atrophic gastritis and gastric carcinoma are two
other conditions associated with hypo- or achlorhydria
and subsequent hypergastrinemia [43–46]. We pro-
posed [45] that H. pylori-induced atrophic gastritis and
subsequent gastric cancer are causally related to exces-
sive release of gastrin that stimulates the tumor cell
growth and induces (together with other growth factors)
the expression of cyclooxygenase-2, leading to angio-
genesis and reduced apoptosis. Gastrinemia may occur
in association with normal or slightly increased gastric
acid secretion in pheochromocytoma, rheumatoid
arthritis, diabetes mellitis, vitiligo, gastroparesis, gastric
outlet obstruction, renal insufficiency, retained antrum,
incomplete vagotomy, and massive resection of the
small bowel [47,48].
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Figure 5. Post translational processing steps involving proteolytic
cleavage and carboxyl-terminal amidation resulting in forma-
tion of various molecular species; gastrin including amidated
gastrin-17 (G-17) and gastrin-34 (G-34). This process may
be altered in gastrinoma cells, releasing into circulation some
progastrin, that is a signal of tumor metastasis.
Figure 6. H. pylori infection of stomach may result in atrophic gastritis
and cancerogenesis but in gastrinoma results in further
increase in gastric production and tumor growth that may be
partly suppressed by H. pylori eradication.
CS48
Med Sci Monit, 2002; 8(6): CS43-59Case Study
Differential diagnosis of gastrinoma: provocative
tests
To differentiate between the many causes of hypergas-
trinemia, a variety of provocative tests [49–53] have
been developed. The secretin test has proved to be the
easiest and most reliable study to perform. Isenberg and
associates [50], in seeking to determine whether the
putative enterogastrone secretin could inhibit acid
secretion, made the serendipitous observation that,
instead, the peptide induced a dramatic increase in plas-
ma gastrin and acid secretion in patients with Z-E syn-
drome. Because secretin did not have a stimulatory
effect on gastrin release in normal subjects, the response
noted in gastrinoma patients was a paradoxical one.
However, recent reports state that secretin can induce a
significant early increase (albeit low) of serum gastrin
levels in a few normal subjects and patients with com-
mon duodenal ulcer disease [53] and rarely in individu-
als with achlorhydria [54]. The mechanism by which
secretin stimulates the release of gastrin from endocrine
neoplasms is unclear. Various reports have indicated
that secretin directly stimulates gastrin release from dis-
persed gastrinoma cells [55,56]; however, no such stim-
ulation was observed when similar experiments were
performed with cultured antral G cells. The fundamen-
tal biological difference between gastrin-releasing cells
present in gastrinomas and G cells found in normal gas-
trointestinal mucosa remains unknown. It is possible
that the different ontogenic origins of these two cell
populations accounts for their different behavior. As
noted above, gastrinoma cells are thought to arise in the
pancreas from pluripotent ductular elements that may
retain the functional characteristics of their normal
counterparts that secrete HCO3
– in response to secretin.
When conducting secretin test it is important to use
purified secretin obtained e.g. from Kabi (GIH
secretin). In the standard protocol, 2 units of secretin
per kg body weight is infused by intravenous bolus, and
serum for gastrin measurement is obtained 10 minutes
and 1 minute before, and at 2, 5, 10, 15, 20, and 30
minutes after secretin injection (Fig. 7). Greater than
90% of gastrinoma patients exhibit an increase in serum
gastrin within 15 minutes of secretin administration.
Based on several studies composed of small numbers of
patients, various criteria for establishing the positivity of
a secretin provocative test have been proposed, includ-
ing increases in serum gastrin of 100 pg/mL, 200
pg/mL, or 50% above basal levels. Although it has been
suggested that an increment in serum gastrin of greater
than 200 pg/mL above basal levels has a sensitivity and
specificity of greater than 90% for the diagnosis of Z-E
syndrome, it was not until the large-scale study by
Frucht and colleagues [57]. These investigators prospec-
tively evaluated the secretin provocative test and the cal-
cium infusion study in 80 gastrinoma patients. In
accord with previous studies, the secretin test was found
to be positive in 87% to 93% of all patients with Z-E syn-
drome and proved to be more advantageous than the
calcium infusion study because of its greater sensitivity,
shorter sampling time, ease of performance and lack of
side effects. Of the three criteria for positivity, the para-
meter recommended by the authors for establishing the
diagnosis of Z-E syndrome was an increase in serum
gastrin of 200 pg/mL or greater. The false-positive
secretin test results reported in other studies [57] were
not seen with these criteria.
The less commonly employed provocative test is the cal-
cium infusion study. Calcium gluconate is administered
at a concentration of 5 mg/kg body weight per hour for
3 hours with simultaneous measurement of serum gas-
trin levels at 30-minute intervals. Greater than 80% of
gastrinoma patients demonstrate an increase in gastrin
levels of more than 400 pg/mL during the third hour of
calcium infusion. This study is less sensitive and specific
than secretin stimulation for identifying patients with Z-
E syndrome. An increase is usually not seen in patients
with common peptic ulcer disease or in normal individ-
uals but may be observed in 50% of patients with hyper-
gastrinemia of gastric origin. As outlined above, lack of
specificity, diminished sensitivity, and the potential
adverse effects of administering intravenous calcium
have made this provocative test less useful than the
secretin test in diagnosing Z-E syndrome. It is usually
reserved for patients with a negative secretin test in the
presence of gastric acid hypersecretion and a strong
clinical suspicion of gastrinoma [57].
Standard meal studies have been employed to distin-
guish hypergastrinemia of gastric origin (as in G-cell
hyperplasia/hyperfunction) from that of pancreatic ori-
gin (gastrinoma). According to the prevailing dogma, Z-
E syndrome patients have less than a 50% increase in
serum gastrin in response to a meal, and a postprandial
increase in serum gastrin of greater than 100% is char-
acteristic of G-cell hyperplasia/hyperfunction. However,
the studies of Frucht and associates [58] suggest that
50% of patients with Zollinger-Ellison syndrome have a
greater than 50% postprandial increase in serum gas-
trin. Thus, some caution should be maintained in apply-
ing the standard meal study for evaluation of patients
with hypergastrinemia.
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Figure 7. Differential diagnosis of gastrinoma includes the provocative
test with infusion of secretin which results in marked rise in
plasma gastrin in gastrinoma but not in hypergastrinemia
accompanying other conditions such as ordinary peptic
ulceration where secretin causes a decrease in plasma gas-
trin.
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Hypergastrinemia and gastric acid secretion
Since gastrin is a most powerful stimulant of gastric acid
secretion, it is not surprising that basal acid output
(BAO) of 15 mmol/h or greater is found in as many as
90% of patients with gastrinoma [59,60]. It is important
to note, however, that 12% of patients with common
duodenal ulcer disease can also manifest increased lev-
els of acid secretion. BAO of greater than 5 mmol/h is
found in 55% of patients with Z-E syndrome, even after
surgery [61]. To enhance the sensitivity of the gastric
secretory studies, maximal acid output (MAO) values
also may be measured using pentagastrin (2 µg/kg-h).
Because gastrinoma patients are presumed to have near
maximal secretion of gastric acid even under basal con-
ditions, the acid secretory response to exogenously
administered secretagogue (pentagastrin) is diminished.
Accordingly BAO/MAO ratio of greater than 0.6 is high-
ly suggestive of Zollinger-Ellison syndrome [2] although
a ratio of less than 0.6 does not exclude the diagnosis
[61].
Since the specificity of gastric acid secretory tests may
not be high and as pointed out by Spindel and col-
leagues [49], about 59% of patients with elevated serum
gastrin levels were either hypo- or achlorhydric; there-
fore, the ability to diagnose Z-E syndrome was
enhanced by performing gastric analysis under natural
conditions by measuring 24 h intragastric pH. Thus,
under optimal circumstances, acid secretory studies
should be part of the diagnostic evaluation in patients
suspected of having gastrinomas. If the equipment for
24 h pH-metry is available, the test should be per-
formed and if in the 24 h period the intragastric pH is
over 3.0, it essentially rules out the diagnosis of Z-E syn-
drome.
In summary, no single diagnostic test has a sensitivity or
specificity of 100% in evaluating patients for Z-E syn-
drome. One must juxtapose the information obtained
from the various tests with the clinical presentation. A
fasting gastrin level of greater than 1000 pg/mL and a
basal acid output of greater than 15 mEq/h in a patient
with recalcitrant peptic ulcer is virtually diagnostic of
Zollinger-Ellison syndrome. In the absence of this triad
of findings, provocative testing may be required. Of
these, the secretin stimulation test offers the greatest
sensitivity and specificity.
Localization of gastrinoma and its metastasis
Gastrinomas are notoriously difficult to localize and the
availability of potent antisecretory drugs has significant-
ly decreased the morbidity and mortality associated with
uncontrollable acid hypersecretion; thus, emergency or
urgent total gastrectomy is rarely if ever needed. How-
ever, recent studies indicate that the tumor itself, rather
than the acid hypersecretion, is responsible for the
adverse sequelae associated with Zollinger-Ellison syn-
drome. Series of patients who eventually underwent
surgery for Zollinger-Ellison syndrome prior to the
1990s noted the inability to identify the tumor in
approximately 30% to 50% of patients, with more than
20% having metastatic disease at laparotomy [61–63].
More recent series, perhaps reflecting improvements in
preoperative imaging modalities, have localized tumor
in 85% of cases, although metastatic disease is frequently
present (approximately 50% of patients). Early interven-
tion with resection of a localized primary tumor pre-
sents the only opportunity to cure this disease [64,65].
In addition, preoperative detection of metastatic disease
will prevent unnecessary surgery. Accordingly every
effort should be made to localize the tumor preopera-
tively.
Many approaches have been used for the purpose of
localizing gastrinomas. These include abdominal ultra-
sonography [66,67], CT scanning [68,69], abdominal
arteriography [70,71], selective portal venous sampling
for gastrin [72,73], endoscopic ultrasonography (UES)
[74–76] and, most recently, somatostatin receptor
scintigraphy (SRS) with the somatostatin analog
octreotide [77,78] (see Fig. 8).
Ultrasonography (USG)
In general, transcutaneous abdominal ultrasonography
is not considered useful for the diagnosis of gastrino-
mas. Most gastrinomas are small; therefore, sensitivity
of this test is quite low, as demonstrated in a prospective
study [79] in which transcutaneous ultrasonography was
able to localize tumors in only 20% of patients later
shown by surgery to have gastrinomas. Nevertheless, if
a lesion is seen, it is likely to represent gastrinoma; thus,
Figure 8. Scheme of diagnosis and management of Z-E syndrome
based on somatostatin receptor scintigraphy (SRS) (modi-
fied from Modlin and Sachs, 1999).
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the specificity of ultrasonography was 90% to 100% in
this prospective series. This examination may be useful
in identification of gastrinoma metastasis.
Endoscopic ultrasonography (EUS) has facilitated high-
resolution imaging of the pancreas, permitting delin-
eation of structures smaller than 5 mm in size. Because
the accuracy of this procedure in diagnosing small pan-
creatic carcinomas approaches 100% [80], it is not sur-
prising that this diagnostic modality is useful in localiz-
ing small neuroendocrine tumors of the pancreas as
well. Rösch and associates [81] reported 37 patients with
surgically confirmed endocrine neoplasms of the pan-
creas (39 tumors), in whom preoperative ultrasonogra-
phy and CT scan of the abdomen yielded negative find-
ings. Thirty-two of the tumors were diagnosed by endo-
scopic ultrasonography (82% sensitivity) with a specifici-
ty of 95%. Tumors varied in size between 0.5 and 2.5
cm in diameter. It is important to note, however, that all
seven of the gastrinomas in this series were located in
the pancreas, and none were located in extrapancreatic
sites, such as the duodenum.
EUS has been used as a primary diagnostic tool to local-
ize neuroendocrine tumors, evaluating over 60 patients
in a prospective study [82]. Thompson et al. [83] report-
ed the results of a prospective study of 16 and then 44
patients with neuroendocrine tumors, some with Z-E
syndrome and found hat the sensitivity of EUS results
in predicting an extrapancreatic gastrinoma was 100%.
This suggests that this procedure should be used early
in the evaluation of a patient with Z-E syndrome. The
sensitivity of EUS in detecting gastrinomas has been
confirmed by Ruzniewski at al. [84]. Of note, they
observed that conventional endoscopy had a sensitivity
of 40% for detecting duodenal wall lesions; thus, EUS
has small incremental utility over endoscopy to localize
duodenal wall lesions. These recent studies support
EUS as a sensitive diagnostic test that should be used in
experienced centers to localize gastrinomas in patients
who have no evidence of metastatic disease.
Other centers without EUS experience have reported
the utility of intraoperative ultrasonography, which
appears to be useful in the localization of small gastrino-
mas [85,86]. Tumors not detected by the surgeon
through manual inspection may be imaged using this
technique, with a sensitivity of 95% by experienced
operators.
Computed Tomography (CT)
The diagnostic efficacy of CT scanning appears to be
improving with the technology itself. For extrahepatic
gastrinoma, CT scanning with intravenous contrast had
a specificity of 95%, a sensitivity of 59%, a positive pre-
dictive value of 96%, and a negative predictive value of
54%. For gastrinomas metastatic to liver, CT scanning
had a specificity of 98%, sensitivity of 72%, a positive
predictive value of 93%, and a negative predictive value
of 90%. Tumor size and location appear to be the key
determinants in the successful diagnosis of gastrinoma
by CT scanning. Approximately 80% of tumors in the
pancreas and tumors larger than 3 cm are detected.
Only 40% of extrapancreatic lesions and no tumors
measuring less than 1 cm in diameter are detectable by
CT scanning. The sensitivity and specificity of comput-
erized axial tomography does not appear to be
enhanced by performing dynamic studies; therefore,
routine scans with oral and intravenous contrast will
suffice. Whether helical techniques will lead to impro-
ved sensitivity remains uncertain, although an initial
report (requiring further comparative study) has
reported 82% sensitivity for tumor localization.
Magnetic Resonance Imaging
Magnetic resonance imaging [87,88] has been evaluated
for the detection of both primary and metastatic gastri-
noma, and initial results appear similar to CT scanning.
In a prospective study, the NIH group found that MRI
using short-time inversion-inversion recovery sequences
was superior to CT for the detection of liver metastases
(sensitivity 71% versus 42%). MRI was equivalent to CT
in detection of primary lesions, leading this group to
suggest that it should replace CT as the cross-sectional
imaging test of choice. The ability of SRS to localize
occult liver metastases leaves the choice between CT and
MRI a consideration of availability and local expertise.
Somatostatin Receptor Scintigraphy (SRS)
Gastrinomas express somatostatin receptors. Therefore,
targeted nuclear scanning following injection of an iso-
topic analog of somatostatin – either 123I-Tyr3-octre-
otide or 111In-DTPA-Dphe1-octreotide [77,78,89,90] –
are emerging as readily available, noninvasive tests to
localize gastrinomas with a sensitivity and specificity of
greater than 75% (Fig. 9). The indium analog (111In-
Pentetriotide) was recently approved by the U. S. Food
and Drug Administration and is marketed as Sando-
statin Lar (Novartis). In a recent prospective compari-
son, [91] the NIH group found that the scan was more
sensitive than transcutaneous USG, CT and MRI for
localizing both primary and metastatic lesions, with sen-
sitivities of 58%, 90% and 92%, respectively. Cadiot and
colleagues [92] observed that Octreoscan scintigraphy
was very useful in detecting small duodenal lesions (3
mm) and peripancreatic lymph nodes. In a review of
122 patients who underwent SRS to localize primary
Figure 9. Localization of gastrinoma can be achieved by various
method but most elegant and precise is somatostatin recep-
tor scintigraphy (SRS) using labeled somatostatin analog
such as octreotide, binding to tumor cells allows for map-
ping the tumor and its metastasis.
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and metastatic gastrinoma lesions, the NIH group
noted that SRS altered management in 47% of patients,
with its greatest impact in the detection of liver metas-
tases [91]. The investigators concluded that SRS should
become the initial imaging modality of patients with gas-
trinoma.
In summary, surgical cure of Z-E syndrome requires
accurate tumor localization. To avoid unnecessary
laparotomy, metastatic disease should be excluded by
either the Octreoscan or by MRI or CT. If no metastatic
disease is found, the approach to localize disease in the
peripancreatic region is governed by local expertise and
surgical experience. In the management of Z-E syn-
drome, it is clear that a team approach to localization
and surgical exploration appears essential to ensure
curative resection.
Therapy
When considering the therapy of patients with Z-E syn-
drome, it is important to achieve two objectives; control
of gastric acid hypersecretion and treatment of the
malignant neoplasm. The emphasis placed on each of
these objectives has shifted over the past 3 decades. Ini-
tially, total gastrectomy appeared to be the only alterna-
tive for effective treatment of the potentially lethal ulcer
disease, and less attention was directed at tumor exci-
sion because many of the patients died from ulcer com-
plications long before their tumors became problematic.
With the advent of histamine H2-R antagonists such as
cimetidine, ranitidine and famotidine, an effective ulcer
therapy, long-term medical management became the
favored approach, with tumor excision only as sec-
ondary consideration because the likelihood of finding
and removing primary a gastrinoma tumor seemed rel-
atively remote [93]. The availability of highly effective
antisecretory therapy through H+,K+-ATPase antago-
nists or PPI such as omeprazole, lansoprazol or panto-
prazole has led to a significant reduction in mortality
related to the complication of acid peptic disease. Under
these circumstances, it has become increasingly appar-
ent that the major cause for morbidity and mortality in
Z-E syndrome is widespread metastatic disease [94];
thus, early tumor detection and excision has assumed
primary importance.
Medical Therapy
The primary aim of medical therapy in Z-E syndrome is
control of gastric acid hypersecretion. The development
of histamine H2-R antagonists was a major break-
through toward this aim. Cimetidine, the first of these
agents, proved to be very efficacious in controlling acid
hypersecretion and prompted ulcer healing and symp-
tom improvement in over 80% of patients with Z-E syn-
drome treated on a short-term basis [95]. However,
over a longer term, these patients often required pro-
gressive increases in the frequency and dose of medica-
tion. To correct this problem, anticholinergics (piren-
zepine) were used as adjunctive therapy, but significant
adverse effects were noted [96]. The efficacy of H2-R
antagonists in inhibiting acid secretion, relieving dys-
peptic symptoms duration of action such as ranitidine
and famotidine have since been developed and have
proved to be efficacious in relieving symptoms and pro-
moting ulcer healing in gastrinoma patients [97]. Famo-
tidine has a 30% longer duration of action and an order
of magnitude greater potency than cimetidine and rani-
tidine [98]. These features, coupled with its efficacy and
safety, make famotidine the H2-R antagonist of choice
for the treatment of Z-E syndrome.
H2-R antagonists with greater potency and for the treat-
ment of Z-E syndrome is the substituted benzimidazoles,
of which omeprazole is the first [99]. More recently, lan-
soprazole and pantoprazole have been added to this
family of drugs [100]. These compounds are the most
potent acid inhibitory agents because they covalently
bind to H+-K+-ATPase, the enzyme responsible for the
generation and secretion of H+ in the parietal cell can-
naliculi. An important new class of drugs made available
and promoting ulcer healing in gastrinoma patients has
been established [101].
Although earlier studies suggested that the doses of
omeprazole required for effective inhibition of acid
secretion in gastrinoma patients were significantly high-
er than in patients with standard peptic ulcers, a study
by Metz et al. [102] suggest that the currently recom-
mended maintenance dose of omeprazole (approxi-
mately 60 mg/d) used in these patients is too high.
Accordingly a gradual reduction of omeprazole dose has
been recommended once the initial dose required for
adequate control of gastric acid hypersecretion (as
described above) has been achieved. More recently, the
NIH group prospectively examined the effectiveness of
low doses of omeprazole (20 mg/d) as initial therapy in
gastrinoma patients [103]. Forty-nine patients were
started on omeprazole (20 mg/d) in an inpatient setting.
Symptoms and gastric acid output were measured.
Patients were considered to have failed low-dose
omeprazole if they developed symptoms or basal acid
output was greater than 10 mmol/h after 3 days of ther-
apy. Using these criteria, low-dose omeprazole was suc-
cessful in 68% of patients. Failures were equally distrib-
uted among persistent symptoms and high gastric out-
put. Based on these results, the investigators continue to
recommend initiating omeprazole therapy at a dose of
60 mg/d. This dose will allow rapid control of gastric
acid secretion, thus minimizing complications related to
peptic diathesis. Once an adequate maintenance dose is
achieved, tapering the medication is then indicated
while following symptoms and acid output (as outlined
above). Tachyphylaxis is observed less frequently with
omeprazole than with H2-R blockers. One concern with
long-term omeprazole therapy has been its potential for
inducing enterochromaffin cell hyperplasia. A prospec-
tive study following 40 patients with Z-E syndrome who
were treated with omeprazole for a mean of 29 months
(6 to 51 months) reported no evidence of hematologic,
biochemical, or gastric toxicity [104]. Their marked
potency, prolonged duration of action, and safety pro-
file make substituted benzimidazoles the treatment of
choice for peptic disease in patients with Z-E syndrome.
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Somatostatin is a known peptide inhibitor of gastric acid
secretion and gastrin release [105]. The biochemically
stable analog of somatostatin, octreotide, has been used
with varying success in patients with gastrinomas
[106,107]. One rationale for the use of somatostatin
analogs is that they can inhibit the secretion of gastrin
from the tumor as well as the action of gastrin on the
oxyntic mucosa. At present, however, these compounds
are available only in injectable form; thus, they are
rarely used as the first-line agent in the treatment of
patients with Z-E syndrome.
Surgical Therapy
Prior to the advent of potent antisecretory agents, total
gastrectomy was the treatment of choice in gastrinoma
patients. Although initial operative mortality was very
high (15% to 20%) [108], a total gastrectomy offered bet-
ter long-term survival than did more conservative
approaches. Increased experience and earlier diagnostic
testing have reduced the operative mortality rate associ-
ated with total gastrectomy to less than 5% [109]. Never-
theless, the new gastric antisecretory agents have obviat-
ed the need for total gastrectomy, and presently this
procedure should be considered only in the rare patient
with nonresectable gastrinoma in whom aggressive
medical therapy has failed, or in those individuals who
cannot take oral medications. Another operation
applied in the past as an adjunct to medical therapy in
patients with Z-E syndrome is proximal gastric vagoto-
my. The rationale for this operation was the high failure
rate with H2-R antagonists. Richardson and associates
[110] reported on a series of 22 gastrinoma patients
who underwent surgery to remove any visible tumor
and then were treated with parietal cell vagotomies.
Selective vagotomy decreased basal acid output signifi-
cantly in all of the patients, even if the tumor was not
localized or incompletely resected. When compared
with preoperative values, basal acid outputs were
reduced by 41% to 69% in patients who had residual
tumor, and the dosage of H2 antagonist required for
therapy was reduced in 21 of 22 patients. Recent follow-
up of these patients (16 years) reveals that 86% of
patients have had long-term inhibition of acid secretion,
with 8 individuals discontinuing antisecretory agents. In
an editorial that followed, it was recommended that
parietal cell vagotomy be routinely performed at the
time of surgical exploration for a gastrinoma [111].
Clearly, the appropriate surgical approach for therapy
of Zollinger-Ellison syndrome today is curative resection
of the neoplasm. Although initial series reported a cure
rate of less than 10% following tumor resection, present
data indicate that cure may be possible in as many as
30% of cases. Improved diagnostic capabilities have led
not only to a reduction in unnecessary surgery on
patients with metastatic disease, but also to the identifi-
cation of extrapancreatic neoplasms with increasing fre-
quency [112]. Studies have reported the incidence of
extrapancreatic lesions to be as high as 66% and resec-
tion of these lesions to be associated with a high likeli-
hood of long-term cure [113]. Operative management
of Zollinger-Ellison syndrome should be undertaken by
a surgeon with expertise in the treatment of islet cell
tumors. Careful and detailed mobilization and explo-
ration of the entire pancreas and surrounding areas
should be performed [114,115]. Any tumors that are
found in the region of the pancreatic head should be
enucleated, and tumors located elsewhere should be
resected with great care. In the event that a tumor is not
found at surgery, distal pancreatectomy should be
avoided because greater then 80% of the gastrinomas
are located within the gastrinoma triangle. If a lesion is
found in the head of the pancreas, a Whipple proce-
dure should be considered with great care because the
mortality of this surgical procedure may outweigh its
potential benefits. However, the decision may be facili-
tated if complete tumor excision is not possible by a less
invasive procedure [108].
Prognosis in gastrinoma
Z-E tumors can be classified as either benign or malig-
nant [11,116]. This classification is not based on tumor
histopathology but on a series of clinical characteristics.
Of these characteristics, tumor extent is one of the most
important prognostic indicators. As reviewed by Maton
at al. [116] 5-year survival rates for all gastrinoma
patients vary between 62% and 75%, and 10-year sur-
vival rates vary between 47% and 53%. If one segregates
the survival data according to extent of tumor present
at the time of diagnosis, patients who have a negative
laparotomy or have all of their tumor removed surgical-
ly have 5- and 10-year survival rates of greater than
90%. In contrast, patients with tumors that were incom-
pletely resected have 5- and 10-year survival rates of
43% and 25%, respectively. More recently Weber et al.
[11] critically evaluated 185 consecutive patients with Z-
E syndrome and identified the criteria that determined
metastatic rate and survival in these individuals. These
investigators confirmed that both a benign and a malig-
nant category of gastrinomas exist. The overall 10-year
survival rates were 93% for patients with MEN I and
74% for patients without MEN I, which are somewhat
better than rates reported previously, but similar to
results reported by Eriksson et al. [117]. It was also
found by these investigators that there was no differ-
ence in survival for the following patients: those ren-
dered disease free at surgery, those with tumor and per-
sistent disease after surgery, and those with disease and
negative exploratory laparotomy results. A poor clinical
outcome is seen in female patients, in patients without
MEN I, in individuals with high serum gastrin, in
patients with a large pancreatic tumor, and in individu-
als with hepatic metastasis. Presence of hepatic metasta-
sis clearly indicates a poor outcome in Z-E syndrome. In
a review of 36 gastrinoma patients [112] those found to
have tumors in the liver at the time of initial evaluation
had a mortality rate of greater than 80% over a 5-year
period. Absence of a detectable tumor or metastasis lim-
ited to lymph nodes was associated with a remarkably
good outcome. On the other hand, altered amino- to
carboxyl-terminal gastrin-17 ratios [33,34], elevated lev-
els of progastrin [118] and the presence of an aneu-
ploidy state in the tumor [119] seem to suggest a poor
prognosis, but confirmatory studies are needed.
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HISTORY OF DISEASE
Beginning of Z-E syndrome
F.J. patient was born November 23, 1934. Symptoms
began June 1964 i.e. at her 30 yr age with an intense
hunger pain in the gastric region, accompanied by vom-
its. At that time, her gastric secretion, both BAO and
pentagastrin-induced MAO were increased, respective-
ly, to 15.4 and 21.6 mmol/h with the ratio of BAO/MAO
being 0.71. Because of high BAO/MAO ratio, the Z-E
syndrome was suspected, and the bioassay of plasma
gastrin was measured using deproteinated plasma
injected i.v. into gastric fistula rats. Since the gastric
secretion in response to plasma extract increased 2–4
times, the existence of the hypergastrinemia was sus-
pected.
Gastric operations due to gastrin-related acute ulcer
diathesis and its complications
On October 1964 FJ (at her 30 yr) was hospitalized for a
gross bleeding from upper part of gastrointestinal tract
and antrectomy plus left vagotomy was performed (I).
After this procedure, the remission of ulcer diathesis
was observed for 2 years but then in 1966 dull pain in
the left upper abdominal region took place. Multiple
gastric, duodenal and jejunal ulcers were recognized
and re-bleeding from upper part of gastrointestinal
tract occurred. Patient underwent partial gastrectomy
with the Billroth type II anastomosis (II). Soon, puru-
lent gallbladder with gall-stones was excised in 1967
(III). Because of stomach ulceration with bleeding, right
vagotomy was concluded in 1968 (IV). Antacids includ-
ing aluminum hydroxide containing preparation (Alu-
gastrin) and anticholinergics (Probanthine) were pre-
scribed and used till 1976 when again acute upper
abdominal pain occurred and our patient was again
hospitalized. Three weeks later, the anastomotic ulcer
was found by gastroscopy. The first measurement of
immunoreactive gastrin level in serum was performed
in Department of Physiology, Academy of Medicine,
Krakow in 1977 using antiserum No 4562 (from Profes-
sor J. F. Rehfeld, Copenhagen, Denmark) showing ami-
dated serum gastrin G-17 and G-34 level of about 2000
pg/mL. The hypergastrinemia was confirmed the same
year in the lab of CURE by Dr John Walsh from Veter-
an Administration Center, Los Angeles, Ca, showing
serum level gastrin of about 2000 pg/mL. The patient
obtained new therapeutic agents that became available
for the limited clinical trial including firstly H2-blockers
(Metiamide, Cimetidine and finally Ranitidine), each
agent working very well during first months but then its
efficacy declined and required either higher dose or
change of the agent.
On 1989, the presence of stomal ulcer was recognized
by upper endoscopy. The H. pylori infection was identi-
fied by positive CLO test and histology of the oxyntic
mucosa obtained during upper endoscopy but the 13C-
urea breath test gave negative results. The IgG antibod-
ies against both H. pylori and its CagA cytotoxin IgG
antibodies were found by ELISA in the serum. H. pylori
eradication was performed using therapy consisting of
Metronidazole (500 mg bd, Amoxicilin (500 mg bd) and
Ranitidine (150 mg td) and one month later the UBT
Figure 10. Endoscopy of the gastric remnant showing modular hyper-
plasia of preserved gastric mucosa (with carcinoid foci).
Figure 11. Histology of retained gastric mucosa at gastric stamp
showing carcinoid cells infiltrating lamina propria.
Figure 12. Chronic atrophic gastritis with foci of complete intestinal
metaplasia at the gastric Stamp.
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and CLO of endoscopic mucosa sample were negative
but no change in serum anti-H. pylori IgG and CagA
were observed. Serum gastrin level which averaged
about 2500 pg/mL was partly reduced (to 2100 pg/mL)
when measured one moth after the eradication therapy.
In 1996, general malaise occurred accompanied by the
reduction in body weight. The upper gastroscopy
showed the presence of stomal ulcer and the biopsy
specimens showed gastric mucosal hyperplasia with
small ECL carcinoid foci and the presence nodular
hyperplasia of ECL cells with admixture of the gastrin
containing cells in the remaining oxyntic mucosa as
assessed in Department of Pathomorphology by one of
us (Dr T.S.), using the gastric biopsy samples obtained
by another coauthors (Dr A.B.) in Department of
Surgery, College of Medicine, Krakow. Colonoscopy
revealed the presence of hyperplastic polyps in descend-
ing colon.
PPI treatment was initiated (Omeprazole, Pantoprazole
and finally Lansoprazole). Follow-up examinations (gas-
troscopy) were performed at 1–6 month intervals during
years 1997–1998 showing chronic atrophic gastritis with
nodular ECL hyperplasia in the small area of oxyntic
mucosa. The endoscopy performed on March 2001 and
March 2002 showed almost similar endoscopic picture
(Fig. 10). The biopsies showed ECL nodular hyperplasia
and the presence of gastric mucosa with carcinoid cells
(ECL-cells) infiltrating lamina propria (Fig. 11). In the
biopsy taken from gastric stamp, chronic atrophic gastri-
tis with focal complete intestinal metaplasia was observed
(Fig. 12). Endocrine cells were also detected in the lami-
na propria at the gastric stamp and found to stain with
chromogranin (Fig. 13). In addition the presence of scat-
tered gastrin-containing endocrine cells were identified
in the mucosa at the gastric stamp (Fig. 14).
Somatostatin Receptor Scintigraphy (SRS) was done on
March 2001 at the Department of Endocrinology,
Jagiellonian University Hospital, showing large tumor
at the gate of liver and metastasis at the pancreas (Fig.
15). In April 2001 both ultrasonography (USG) (Fig. 16)
and Computer Tomography (CT) (Fig. 17) were per-
formed showing the tumor of cyclic shape just at the
liver and another smaller at the head of the pancreas.
Figure 13. Marked modular hiperplasia of chromogranin containing
endocrine cells in the lamina propria at the gastric stamp.
Figure 14. Some endocrine cells in the lamina propria staing for 
gastrin.
Figure 15. SRS with accumulation of labeled octreotide in the larger
metastasis at liver gate and in the smaller focus in the tail of
the pancreas as assessed 48h after administration of 111In-
octreotide.
Figure 16. USG of the liver with visible large tumor in the right lobe of
this organ.
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The pH-metry (Fig. 18) performed under fasting condi-
tions in the gastric remnant showed normal acidity of
gastric juice with mean pH of less than 3.2 despite of
the fact that the total area of the oxyntic mucosa in gas-
tric remnant is small (about 2–4 cm2). During the San-
dostatin Lar therapy (20 mg/dose), the pH-metry did
not show any decrease below the value of 4–5, indicat-
ing complete achlorhydria.
DISCUSSION
This case report shows that the gastrinoma may develop
for decades spreading metastasis into liver and inducing
ECL nodular hyperplasia with carcinoid formation in
the remnant gastric mucosa and polypoid hypertrophy
of the colon mucosa. The major source of initial compli-
cations in this case was hypersecretion of gastric acid
causing various types of ulcerations including gastro-
duodeno-jejunal and stomal (after gastrectomy) ulcera-
tions and bleeding. It greatly declined after almost total
gastrectomy and then remained under medical control
using various drugs for almost four decades.
At the time when the disease was recognized as Z-E syn-
drome, almost four decades ago, it was generally
believed that the removal of the stomach, the major tar-
get organ for gastrin produced in enormous amounts
by gastrinoma tumor cells is the best way of treatment
but, our patient did no agree for such gastrectomy.
With an advent of powerful gastric acid inhibitors
Figure 17. The CT scan at the level of liver, showing polycyclic tumor
(106 x 54 mm) with sings of necrosis. Smaller tumor was
found below the lower pol of left kidney (40 x 45 mm). The
visible cyclic metastases at the liver and below the kidney
are encircled on the picture shown above.
Figure 18. Tracing of 24 h pHmetry in gastric remnant during fasting period at night and just after breakfast (upper tracing) and after inhibition of gas-
tric secretion following administration of sandostatin Tar (octreotid), (Nowartis, Poland).
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including H2-R antagonists and then PPI, the removal
of the stomach was not anymore considered as ultimate
goal of therapy because the complications of acute ulcer
diathesis could be successfully controlled and prevented
by suppression of gastric acid and the elimination of the
aggressive factor such as acid-pepsin secretion. Thus,
complete gastrectomy could not been considered as the
treatment of choice even if the primary tumor cannot be
detected and our case supports this option. Our patient
was in unusually favorable situation because our
Department of Clinical Physiology of Jagiellonian
University in Cracow collaborated with numerous phar-
maceutical companies such as Glaxo, UK, Hassle then
AstraZeneca, Sweden, Byk-Gulden-Roland, Germany,
Krka, Slovenia, Boehringer, Germany, Searle, USA,
Yamaguchi, Japan, Polfa, Pabianice, Poland) in per-
forming preclinical studies and then phase I and II
studies. These agents including H2-R antagonists (meti-
amide, ranitidine, famotidine), anticholinergics (piren-
zepine), somatostatin analog (Sandostatin), methylated
PGE (Mizoprostol) and PPI (omeprazole, pantoprazole,
lanzoprazole, Prazol) were also available for our Z-E
syndrome patient for almost three decades. Our patient
was given most of these agents and as a rule, almost
each of them (except Mizoprostol which was soon with-
drawn because of severe diarrhea) initially worked per-
fectly during first few months but then tachyphylaxis
developed and ulcer recurrence with complications,
mainly bleeding, reappeared requiring the change of
the treatment regimen. Despite often ulcer recurrence
and its complications, our patient never agreed for com-
plete gastrectomy but instead was subjected to nume-
rous gastric operations carried out in various depart-
ments of surgery in Poland and leaving at the outcome
the gastric remnant of the area of few cm2 at gastric
stamp.
At the beginning of the disease, 38 years ago, very high
basal gastric acid secretion (BAO = 15.4 mmol/h) with
characteristic increase of the BAO/MAO ratio reaching
0.71 was recorded. This hyperchlorhydria was accompa-
nied by extremely high serum gastrin level exceeding
2000 pg/mL. The hypergastrinemia before the era of
radioimmunoassay described by Yalow and Berson [36]
was initially revealed using simple gastrin bioassay on
gastric fistula preparation in rats similar to that used
originally by Sircus [120] and showing about 3 fold
increase in acid output in response to 5 ml of depro-
teinized serum given intravenously and corresponding
to that achieved with histamine at a dose of 5 mg/kg-h
s.c. This hypergastrinemia in our patient was confirmed
by radioimmunoassay (RIA) of gastrin when it became
available in 1968 in our lab using antiserum No 4562
(kindly provided by Professor J. F. Rehfeld, Department
of Biochemistry, Copenhagen University, Copenhagen,
Denmark) recognizing amidated forms of G-17 and G-
34). Serum gastrin in our patient exceeded 2000 pg/mL
and this highly elevated serum gastrin was confirmed
later by Dr J. W. Walsh at CURE, Los Angeles. At pre-
sent, using the same antiserum, the serum gastrin levels
in our patient ranges from 3.800 to 5.780 ng/mL. In
collaboration with Professor J. W. Rehfeld, we also mea-
sured serum level of progastrin, the precursor of gastrin
that exerts trophic effects on epithelial and cancer cells
but has no gastric acid stimulatory activity. Serum levels
of progastrin was about 156 pM/L, about twice as high
as in healthy controls (80 pM/L). As gastrinoma cell are
equipped with CCKB receptors, it is likely that this pre-
cursor together with gastrin are responsible for the cell
proliferation and tumor growth. The release of progas-
trin by gastrinoma has been reported previously (27)
and suggested to indicate poor prognosis. Anyway, our
study confirms that gastrinoma is capable of releasing
not only excessive amounts of gastrin but also some pro-
gastrin. This study also indicates that the prosttransla-
tional processing of pre-progastrin to gastrin in gastri-
noma cells is disordered and that some progastrin
escaped into the circulation during this posttranslational
process.
It is of interest that about twenty-five percent of gastri-
noma patients have MEN I syndrome [6]. The primary
sites of organ involvement in this autosomal-dominant
genetic disorder include the parathyroid, pancreas,
pituitary, and, less commonly, adrenal cortex and thy-
roid. In a large series by Ballard and colleagues [121]
87% of 85 patients with MEN I had involvement of the
parathyroid glands, 81% had disorders of the endocrine
pancreas, and 65% had pituitary involvement. More
recently, Trump and colleagues [122] reported their
findings in 220 patients with MEN I and observed dif-
ferent rates of organ system involvement, 64 with 95%,
41%, and 30% of patients having parathyroid, pancreat-
ic, and pituitary neoplasms, respectively. Consistent
with other reports, this later study also observed that
parathyroid lesions were the first indication of this
genetic disorder in 87% of patients. The clinical features
of Z-E syndrome (ulcer complications, gastric or pancre-
atic surgery) account for the major morbidity and mor-
tality related to MEN I. [123]. It is important to remem-
ber that the first clinical manifestation of MEN I may be
Z-E syndrome. As noted by Benya and colleagues [124]
up to one third of patients with MEN I and gastrinoma
may present with signs and symptoms of hypergastrine-
mia without manifestation of any additional endo-
crinopathy. Based on this finding, these investigators
suggested that patients with the presumptive diagnosis
of sporadic Z-E syndrome should be monitored bio-
chemically and, when feasible, genetically screened for
evidence of MEN I. The genetic defect in patients with
MEN I has been mapped to the long arm of chromo-
some 11 (11q11-q13) by analysis of restriction fragment
length polymorphism in affected families [122,123]. In
our patient no evidence what so ever was found to sug-
gest the existence of MEN I and the diagnosis of gastri-
noma or Z-E syndrome was established.
Symptoms and signs in patients with Z-E syndrome are
primarily related to gastric acid hypersecretion and its
consequences. Greater than 90% of gastrinoma patients
develop ulcers in the upper gastrointestinal tract at
some point during their disease [5,12]. Presenting ulcer
symptoms are indistinguishable from those associated
with benign peptic ulcer disease, but frequently they will
be less responsive to standard therapy. As in benign
peptic ulcer disease, ulcers in patients with Zollinger-
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Ellison syndrome occur most frequently in the first por-
tion of the duodenum (75%), and are usually solitary.
However, ulcers in gastrinoma patients also may occur
in the second, third, and fourth portions of the duode-
num (14%), as well as in the jejunum (11%) [125]. The
ulcers are usually less than 1 cm in diameter but can
occasionally present as giant lesions. Peptic ulcer disease
refractory to standard medical therapy, recurrent ulcers
after prior gastric surgery, diarrhea in patients with
ulcers, or peptic disease presenting with complications
such as obstruction, perforation, or bleeding suggest a
possible diagnosis of Z-E syndrome. All these changes
including duodeno-jejunal ulcerations, diarrhea and
complications, particularly bleeding were observed in
our patients until almost complete gastrectomy was per-
formed. Since that time periodic stomal ulcerations
accompanied by occasional bleeding were recorded and
treated with various anti-secretory drugs.
Diarrhea that in our patient preceded the diagnosis of
Z-E syndrome and occurred in earlier period of the dis-
ease is considered to be multifactorial, but its depen-
dence on acid hypersecretion is demonstrated by ame-
lioration of symptoms upon continuous nasogastric suc-
tion or inhibition of acid secretion. [2]. Thus, the severe
volume load represented by the acid, which can be
secreted at the rate of several liters per day, can account
for some of the diarrhea. An added feature of the diar-
rhea is steatorrhea and maldigestion [126] which results
from the inactivity of pancreatic enzymes at the low pH
of the duodenum caused by the excessive acid load. The
acidic pH of the small bowel also may lead to damage of
the intestinal mucosa, resulting in a sprue-like state with
flattened intestinal villi and accompanying malabsorp-
tion [127]. Bile acids are poorly soluble in an acid
milieu; thus, Zollinger-Ellison syndrome may result in
decreased micelle formation and subsequent malabsorp-
tion of fat and lipid-soluble nutrients and vitamins.
Concerning the natural history of gastrinoma, Mignon
et al. [128] proposed that that the prognosis depends
upon 1). The size and location of tumor and its spread
to the liver and bones; 2). The size and the location of
primary tumor and its spread with hepatic and bone
metastasis being the major determinants of death; 3).
The resistance of the tumor to conservative therapy.
Anyway the survival in our patient was a record long of
38 years when compared to recently described by Tera-
da et al. [129] another longest survival amounting to 24
years and this could be attributed, at least in part, to
patients’ personal positive attitude to the treatment
given, very good collaboration with therapist and excel-
lent response to the treatment with Sandostatin Lar that
was effective in the marked reduction in plasma gastrin
level, gastric acid output and in tumor size.
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